Bayer expands MIT genome collaboration
This article was originally published in Scrip
Bayer and the Broad Institute of MIT and Harvard are hoping to create new cardiovascular treatments and diagnostics by expanding their collaboration in genomic research, which is currently focused on oncology. The collaboration combines Bayer's expertise in cardiology and the institute's genomics and biology knowhow. The two organizations will focus on genetic discovery, target validation, and drug discovery. A joint steering committee will oversee the collaboration and a joint research committee will supervise research progress and direction. Financial terms of the agreement have not been disclosed. Cardiovascular genomics is an emerging field of cardiology that uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery. Back in 2013 Bayer and the institute struck a five-year collaboration in oncogenomics and drug discovery.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.